Abstract This article analyzes recent clinical data on brachytherapy around the world, as well as the clinical experience from the author and her research team. The author summarizes the indications, contraindications, target volume, dosage, efficacy, and side effects to form a mature brachytherapy regimen. The work may provide a reliable reference for counterparts in China and be helpful for improving brachytherapy. This article mainly discusses brachytherapy for abdominal and pelvic malignant tumors.
Cheng Guanghui. Clinical application of brachytherapy for malignant tumor (2):abdomen and pelvic cavity[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 607-613.
Cheng Guanghui. Clinical application of brachytherapy for malignant tumor (2):abdomen and pelvic cavity[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 607-613.
[1] Collettini F,Singh A,Schnapauff D,et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum[J].Eur J Radiol,2013,82(10):509-514.DOI:10.1016/j.ejrad.2013.04.046. [2] Wybranski C,Eberhardt B,Fischbach K,et al. Accuracy of applicator tip reconstruction in MRI-guided interstitial 192 Ir-high-dose-rate brachytherapy of liver tumors[J].Radiother Oncol,2015,115(1):72-77.DOI:10.1016/j.radonc.2015.01.018. [3] Seidensticker M,Wust P,Rühl R,et al. Safety margin in irradiation of colorectal liver metastases:assessment of the control dose of micrometastases[J].Radiat Oncol,2010,5(1):24-24.DOI:10.1186/1748-717X-5-24. [4] Mohnike K,Wieners G,Schwartz F,et al. Computed tomography–guided high-dose-rate brachytherapy in hepatocellular carcinoma:safety,efficacy,and effect on survival[J].Int J Radiat Oncol Biol Phys,2010,78(1):172-179.DOI:10.1016/j.ijrobp.2009.07.1700. [5] Geisel D,Denecke T,Collettini F,et al. Treatment of hepatic metastases from gastric or gastroesophageal adenocarcinoma with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT)[J].Anticancer Res,2012,32(12):5453-5458. [6] Wybranski C,Seidensticker M,Mohnike K,et al. In vivo assessment of dose volume and dose gradient effects on the tolerance doseof small liver volumes after single-fraction high-dose-rate 192Ir irradiation[J].Radiat Res,2015,172(5):598-606.DOI:10.1667/RR1773.1. [7] Ricke J,Wust P.Computed tomography-guided brachytherapy forliver cancer[J].Semin Radiat Oncol,2011,21(4):287-293.DOI:10.1016/j.semradonc.2011.05.005. [8] Collettini F,Poellinger A,Denecke T,et al. Hepatocellular carcinoma:computed tomography-guided high-dose-rate brachytherapy ablation of large and very large lesions[J].Eur Radiol,2012,22(5):1101-1109.DOI:10.1007/s00330-011-2352-7. [9] Collettini F,Schreiber N,Schnapauff D,et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma[J].Strahlenthere Onkol,2015,191(5):405-412.DOI:10.1007/s00066-014-0781-3. [10] Tselis N,Chatzikonstantinou G,Kolotas C,et al. Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours:a single institution study[J].Eur Radiol,2013,23(8):2264-70.DOI:10.1007/s00330-013-2816-z. [11] Denecke T,Stelter L,Schnapauff D,et al. CT-guided interstitial brachytherapy of hepatocellular carcinoma before liver transplantation:an equivalent alternative to transarterial chemoembolization?[J].Eur Radiol,2015,25(9):1-9.DOI:10.1007/s00330-015-3660-0. [12] Yao LQ,Tang CW,Zheng YY,et al. Percutaneous Transhepatic biliary stenting vs.surgical bypass in advanced malignant biliary obstruction:cost-effectiveness analysis[J].Hepato-Gastroenterol,2012,60(121):563-566.DOI:10.5754/hge123242013;60(121):Ahead of print. [13] Kocak Z,Ozkan H,Adli M,et al. Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct[J].Radiat Med,2005,23(3):200-207. [14] Aggarwal R,Patel FD,Kapoor R,et al. Evaluation of high-dose-rate intraluminal brachytherapy by percutaneous transhepatic biliary drainage in the palliative management of malignant biliary obstruction—a pilot study[J].Brachytherapy,2013,12(2):162-170.DOI:10.1016/j.brachy.2012.06.002. [15] Haie-Meder C,Potter R,Van Limbergen E,et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J].Radiother Oncol,2005,74(3):235-245.DOI:10.1016/j.radonc.2004.12.015. [16] 张宁,程光惠.宫颈癌腔内联合组织间插植近距离放疗应用进展[J].中华放射肿瘤学杂志,2016,25(8):895-901. Zhang N,Cheng GH.Advances in the application of brachytherapy combined with brachytherapy in cervical cancer[J].Chin J Radiat Oncol,2016,25(8):895-901.DOI:10.3760/cma.j.issn.1004-4221.2016.08.023. [17] Sturdza A,Ptter R,Fokdal L U,et al. Image guided brachytherapy in locally advanced cervical cancer:improved pelvic control and survival in RetroEMBRACE,a multicenter cohort study[J].Radiother Oncol,2016,120(3):428.DOI:10.1016/j.radonc.2016.03.011. [18] Tharavichitkul E,Prasitwattanaseree S,Thipmate C,et al. Treatment results of adjuvant brachytherapy as monotherapy in endometrial cancer:a retrospective study from faculty of medicine,chiang mai university[J].J Cancer Ther,2015,06(1):34-39.http://dx.doi.org/10.4236/jct.2015.61005. [19] Dutta SW,Trifiletti DM,Grover S,et al. Management of elderly patients with early-stage medically inoperable endometrial cancer:systematic review and national cancer database analysis[J].Brachytherapy,2017. [20] Tewari K,Cappuccini F,Syed AM,et al. Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer[J].Am J Obstet Gynecol,1999,181(1):91-98. [21] Prempree T,Amornmarn R.Radiation treatment of recurrent carcinoma of the vulva[J].Cancer,1984,54(9):1943-1949. [22] Milosevic MF,Warde PR,Banerjee D,et al. Urethral carcinoma in women:results of treatment with primary radiotherapy[J].Radiother Oncol,2000,56(1):29-35. [23] Hoskin PJ,Colombo A,Henry A,et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer:An update[J].Radiother Oncol,2013,107(3):325-332.DOI:10.1016/j.radonc.2013.05.002. [24] Mohler J,Bahnson RR,Boston B,et al. NCCN clinical practice guidelines in oncology:prostate cancer[J].J Natl Compr Canc Netw,2010,8(2):162-200. [25] Hoskin P,Rojas A,Lowe G,et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence[J].Int J Radiat Oncol Biol Phys,2012,82(4):1376-1384.DOI:10.1016/j.ijrobp.2011.04.031. [26] Galalae RM,Martinez A,Mate T,et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer[J].Int J Radiat Oncol Biol Phys,2004,58(4):1048.DOI:10.1016/j.ijrobp.2003.08.003 [27] Pfeiffer D,Sutlief S,Feng W,et al. AAPM Task Group 128:Quality assurance tests for prostate brachytherapy ultrasound systems[J].Med Phys,2008,35(12):5471-5489.DOI:10.1118/1.3006337. [28] Zelefsky MJ,Pei X,Chou JF,et al. Dose escalation for prostate cancer radiotherapy:predictors of long-term biochemical tumor control and distant metastases–free survival outcomes[J].Eur Urol,2011,60(6):1133-1139.DOI:10.1016/j.eururo.2011.08.029. [29] Yoshioka Y,Yoshida K,Yamazaki H,et al. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer[J].J Radiat Res,2013,54(5):781-8.DOI:10.1093/jrr/rrt027. [30] Demanes DJ,Martinez AA,Ghilezan M,et al. High-dose-rate monotherapy:safe and effective brachytherapy for patients with localized prostate cancer[J].Int J Radiat Oncol Biol Phys,2011,81(5):1286.DOI:10.1016/j.ijrobp.2010.10.015. [31] Kanfir K,Haie-Meder C,Albano M,et al.36 Outcome of patients treated with exclusive brachytherapy for carcinoma of the penis[J].Radiother Oncol,2000,55(00):25-25.https://doi.org/10.1016/S0167-8140(00)81358-4. [32] Crevoisier RD,Slimane K,Sanfilippo N,et al. Long-Term Results of Brachytherapy for Carcinoma of the Penis Confined to the Glans (N-or NX)[J].International Journal of Radiation Oncology Biology Physics,2009,74(4):1150.DOI:10.1016/j.ijrobp.2008.09.054. [33] Crook JM,Jezioranski J,Grimard L,et al. Penile brachytherapy:Results for 49 patients[J].International Journal of Radiation Oncologybiologyphysics,2005,62(2):460-467.DOI:10.1016/j.ijrobp.2004.10.016 [34] Vuong T,Richard C,Niazi T.High dose rate endorectal brachytherapy for patients with curable rectal cancer[J].Semi Colon Rectal Surg,2010,21(2):115-119.DOI:10.1053/j.scrs.2010.01.009. [35] Hesselager C,Vuong T,Phlman L,et al. Short-term outcome after neoadjuvant high-dose-rate endorectal brachytherapy or short-course external beam radiotherapy in resectable rectal cancer[J].Colorectal Dis,2013,47(6):662-666.DOI:10.1111/codi.12193. [36] Gerard JP,Chapet O,Nemoz C,et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy:the lyon R96-02 randomized trial[J].J Clin Oncol,2004,22(12):2404-2409.DOI:10.1200/JCO.2004.08.170. [37] Hoskin PJ,Canha SM,Bownes P,et al. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectalcarcinoma[J].Radiother Oncol,2004,73(2):195-198.DOI:10.1016/j.radonc.2004.06.004. [38] Coatmeur O,Truc G,Barillot I,et al. Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy[J].Radiother Oncol,2004,70(2):177-182.DOI:10.1016/j.radonc.2004.01.016. [39] Jakobsen A,Mortensen JP,Bisgaard C,et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost[J].Int J Radiat Oncol Biol Phys,2006,64(2):461-465.DOI:10.1016/j.ijrobp.2005.07.969. [40] Yanagi H,Kusunoki M,Kamikonya N,et al. Results of preoperative intraluminal brachytherapy combined with radical surgery for middle and lower rectal carcinomas[J].J Surg Oncol,1997,65(2):76-81 [41] Vuong T,Belliveau PJ,Michel RP,et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer:early results of a phase Ⅰ/Ⅱ study[J].Dis Col Rect,2002,45(11):1493-1495.DOI:0.1097/01.DCR.0000029762.67291.AA. [42] Lestrade L,Bari BD,Pommier P,et al. Role of brachytherapy in the treatment of cancers of the anal canal[J].2014,190(6):546-554.DOI:10.1007/s00066-014-0628-y. [43] Widder J,Kastenberger R,Fercher E,et al. Radiation dose associated with local control in advanced anal cancer:retrospective analysis of 129 patients[J].Radiother Oncol,2008,87(3):367-375.DOI:10.1016/j.radonc.2008.05.001. [44] Moureau-Zabotto L,Ortholan C,Hannoun-Levi JM,et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)[J].Int J Radiat Oncol Biol Phys,2013,85(3):135-142.DOI:10.1016/j.ijrobp.2012.09.034. [45] Saarilahti K,Arponen P,Vaalavirta L,et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer[J].Radiother Oncol,2008,87(3):383-390.DOI:10.1016/j.radonc.2008.04.011.
2017, Vol. 26 
